Source - RNS
RNS Number : 5657M
Dechra Pharmaceuticals PLC
14 October 2016




Friday, 14 October 2016


Dechra® Pharmaceuticals PLC

(Dechra, Company or the Group)


Dechra complete acquisition in Australia



Further to the announcement on 16 September 2016, Dechra is pleased to announce that the acquisition of the business and assets of Apex Laboratories Pty Ltd has now completed.



Enquiries to:

Dechra Pharmaceuticals PLC

Ian Page, Chief Executive Officer

Office:  +44 (0) 1606 814 730

e-mail: [email protected]

TooleyStreet Communications Ltd

Fiona Tooley, Director

Mobile: +44 (0) 7785 703 523

e-mail: [email protected]



About Dechra

Stock Code: Full Listing (Pharmaceuticals): DPH

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.  Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 


The Group's Preliminary results for the year ended 30 June 2016 were released on 5 September 2016.  For more information, please visit:


About Apex

Apex, based in Somersby near Sydney, Australia is a pharmaceutical company which manufactures, markets and sells branded non-proprietary prescription and other related companion animal products in Australia and New Zealand. It will give Dechra direct access to the established and growing Australian companion animal product market and will provide a base from which to support and build Dechra's expansion in the Australasian and Asian regions.



Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC. 


Market Abuse Regulation (MAR)

The information contained within this announcement may constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


This information is provided by RNS
The company news service from the London Stock Exchange